129 related articles for article (PubMed ID: 31846475)
1. Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial.
Chandra J; Woo WP; Dutton JL; Xu Y; Li B; Kinrade S; Druce J; Finlayson N; Griffin P; Laing KJ; Koelle DM; Frazer IH
PLoS One; 2019; 14(12):e0226320. PubMed ID: 31846475
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease.
Bernstein DI; Flechtner JB; McNeil LK; Heineman T; Oliphant T; Tasker S; Wald A; Hetherington S;
Vaccine; 2019 Jun; 37(26):3443-3450. PubMed ID: 31103365
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial.
Bernstein DI; Wald A; Warren T; Fife K; Tyring S; Lee P; Van Wagoner N; Magaret A; Flechtner JB; Tasker S; Chan J; Morris A; Hetherington S
J Infect Dis; 2017 Mar; 215(6):856-864. PubMed ID: 28329211
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
[TBL] [Abstract][Full Text] [Related]
5. Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial.
Flechtner JB; Long D; Larson S; Clemens V; Baccari A; Kien L; Chan J; Skoberne M; Brudner M; Hetherington S
Vaccine; 2016 Oct; 34(44):5314-5320. PubMed ID: 27642130
[TBL] [Abstract][Full Text] [Related]
6. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE
JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030
[TBL] [Abstract][Full Text] [Related]
7. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial.
Leroux-Roels G; Clément F; Vandepapelière P; Fourneau M; Heineman TC; Dubin G
Hum Vaccin Immunother; 2013 Jun; 9(6):1254-62. PubMed ID: 23434737
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.
Dropulic LK; Oestreich MC; Pietz HL; Laing KJ; Hunsberger S; Lumbard K; Garabedian D; Turk SP; Chen A; Hornung RL; Seshadri C; Smith MT; Hosken NA; Phogat S; Chang LJ; Koelle DM; Wang K; Cohen JI
J Infect Dis; 2019 Aug; 220(6):990-1000. PubMed ID: 31058977
[TBL] [Abstract][Full Text] [Related]
11. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].
Langenberg AG; Burke RL; Adair SF; Sekulovich R; Tigges M; Dekker CL; Corey L
Ann Intern Med; 1995 Jun; 122(12):889-98. PubMed ID: 7755223
[TBL] [Abstract][Full Text] [Related]
12. An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.
Dutton JL; Woo WP; Chandra J; Xu Y; Li B; Finlayson N; Griffin P; Frazer IH
Hum Vaccin Immunother; 2016 Dec; 12(12):3079-3088. PubMed ID: 27580249
[TBL] [Abstract][Full Text] [Related]
13. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
[TBL] [Abstract][Full Text] [Related]
15. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
[TBL] [Abstract][Full Text] [Related]
16. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
Stanberry LR; Spruance SL; Cunningham AL; Bernstein DI; Mindel A; Sacks S; Tyring S; Aoki FY; Slaoui M; Denis M; Vandepapeliere P; Dubin G;
N Engl J Med; 2002 Nov; 347(21):1652-61. PubMed ID: 12444179
[TBL] [Abstract][Full Text] [Related]
17. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
18. Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial.
Van Wagoner N; Fife K; Leone PA; Bernstein DI; Warren T; Panther L; Novak RM; Beigi R; Kriesel J; Tyring S; Koltun W; Lucksinger G; Morris A; Zhang B; McNeil LK; Tasker S; Hetherington S; Wald A
J Infect Dis; 2018 Nov; 218(12):1890-1899. PubMed ID: 29982727
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
20. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes.
Straus SE; Corey L; Burke RL; Savarese B; Barnum G; Krause PR; Kost RG; Meier JL; Sekulovich R; Adair SF
Lancet; 1994 Jun; 343(8911):1460-3. PubMed ID: 7911177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
